Regeneron and Sanofi Plan to Cut Cholesterol Drug Price in Exchange for Wider Coverage – Wall Street Journal

The makers of an expensive cholesterol-lowering drug plan to offer discounts of up to 69% in exchange for insurers and pharmacy-benefit managers expanding their coverage of the medicine to more patients.

Regeneron Pharmaceuticals Inc. and Sanofi SA said they will seek to renegotiate their contracts with insurers by offering rebates and discounts for the drug, called Praluent, that would bring its U.S. net price within a range of $4,500 to $8,000 annually per patient, down from its list price of $14,600.

Source link

Comments are closed

Featured Links

    Search Archive

    Search by Date
    Search by Category
    Search with Google
    Flirt online

    Flirt online

    Log in | Designed by Gabfire themes